174 related articles for article (PubMed ID: 37326363)
21. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
22. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
23. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
24. Mutation Profile of Resected
Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
[TBL] [Abstract][Full Text] [Related]
25. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.
Choi YL; Sun JM; Cho J; Rampal S; Han J; Parasuraman B; Guallar E; Lee G; Lee J; Shim YM
PLoS One; 2013; 8(2):e56011. PubMed ID: 23468851
[TBL] [Abstract][Full Text] [Related]
26. Frequency and types of
Lemine Sow M; El Yacoubi H; Moukafih B; Balde S; Akimana G; Najem S; El Khoyaali S; Abahssain H; Chaibi A; Zeb Khan S; Trapani D; Benzekri A; Ghaouti M; Gamra L; Mestari A; Kettani F; Rahali Y; Mrabti H; Elghissassi I; Errihani H
Tumori; 2021 Aug; 107(4):335-340. PubMed ID: 33079008
[TBL] [Abstract][Full Text] [Related]
27. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
28. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
Cai W; Lin D; Wu C; Li X; Zhao C; Zheng L; Chuai S; Fei K; Zhou C; Hirsch FR
J Clin Oncol; 2015 Nov; 33(32):3701-9. PubMed ID: 26416997
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
Gao J; Chen JQ; Zhang L; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
[TBL] [Abstract][Full Text] [Related]
31. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.
Ren S; Kuang P; Zheng L; Su C; Li J; Li B; Chen X; Wang Y; KimCurran V; Liu L; Hu Q; Zhang J; Tang L; Zhou C
Cell Biochem Biophys; 2012 Nov; 64(2):155-60. PubMed ID: 22707299
[TBL] [Abstract][Full Text] [Related]
32. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Zheng D; Wang R; Ye T; Yu S; Hu H; Shen X; Li Y; Ji H; Sun Y; Chen H
Oncotarget; 2016 Jul; 7(27):41691-41702. PubMed ID: 27223439
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
34. Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma.
Kim EY; Kim A; Lee G; Lee H; Chang YS
BMC Cancer; 2018 Dec; 18(1):1221. PubMed ID: 30522449
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.
Lee S; Kim Y; Sun JM; Choi YL; Kim JG; Shim YM; Park YH; Ahn JS; Park K; Han JH; Ahn MJ
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1203-11. PubMed ID: 21626008
[TBL] [Abstract][Full Text] [Related]
36. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
[TBL] [Abstract][Full Text] [Related]
37. Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.
Sato S; Nagahashi M; Koike T; Ichikawa H; Shimada Y; Watanabe S; Kikuchi T; Takada K; Nakanishi R; Oki E; Okamoto T; Akazawa K; Lyle S; Ling Y; Takabe K; Okuda S; Wakai T; Tsuchida M
Sci Rep; 2018 Jan; 8(1):1005. PubMed ID: 29343775
[TBL] [Abstract][Full Text] [Related]
38. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
[TBL] [Abstract][Full Text] [Related]
39. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
40. Clinical Characteristics and Molecular Patterns of
Zhang K; Chen H; Wang Y; Yang L; Zhou C; Yin W; Wang G; Mao X; Xiang J; Li B; Zhang T; Fei S
Oncol Res; 2019 May; 27(5):575-582. PubMed ID: 30131091
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]